BACKGROUND Patient satisfaction is an important aspect of patient-centered care but has not been systematically studied after treatment of nonmelanoma skin cancer (NMSC), the most prevalent cancer.
N onmelanoma skin cancer (NMSC) can be successfully treated using different therapies, including destruction (cryotherapy, electrodesiccation and curettage, laser ablation), radiation, surgery (excision, Mohs surgery), and topical chemotherapeutic agents (5-fluorouracil, imiquimod, 5-aminoleuvonic acid with photodynamic therapy). There is substantial variation in treatment selection in different practice settings, 1 and insufficient evidence exists to recommend a single treatment as superior to others for most tumors. [2] [3] [4] Data largely from retrospective studies suggest that recurrence rates are lowest after the most technologically intensive therapy (Mohs surgery) and highest after destruction. 2, 5, 6 Skinrelated quality of life improves similarly after Mohs surgery and excision but does not improve after destruction with electrodesiccation and curettage. 7 In an increasingly patient-oriented health care system, patient satisfaction is an important outcome to guide treatment selection, especially for typically nonfatal conditions such as NMSC. Numerous variables such as the patient's perceptions of practitioner competence and communication, financial aspects associated with care, environmental surroundings, and clinical outcome can influence patient satisfaction. In addition, patient satisfaction has been associated with several other outcomes, including health status, quality of life, adherence to medical advice, and initiation of complaints. [8] [9] [10] [11] We sought to compare patient satisfaction after the three main treatments for NMSC and to determine pretreatment patient, tumor, and care characteristics associated with better short-term and long-term satisfaction.
Materials and Methods

Study Design
Data were obtained prospectively from a cohort of consecutive patients with NMSC diagnosed in 1999 and 2000 at a university-affiliated dermatology practice or the nearby affiliated Veterans Affairs Medical Center (VAMC). The Institutional Review Board at each institution approved the study. Potential study participants were identified using daily review of all pathology records at both institutions. NMSCs were defined as those with a final histopathologic diagnosis of basal cell carcinoma or squamous cell carcinoma (including squamous cell carcinoma in situ). Potential participants were excluded if they were younger than 18, if their records were protected because they were employees, or if they had a previous skin cancer diagnosed during the study period. Participants were considered ineligible if they were physically or mentally unable to complete surveys, did not speak English, or had no current address available. Patients were enrolled if they responded to a pretreatment questionnaire about their health and quality of life.
We restricted the study population to 834 individuals whose tumors were treated using electrodesiccation and curettage (destruction), excision, or Mohs surgery. If a patient had multiple tumors, he or she was asked to respond only about therapy for the most bothersome tumor, and data are reported only about this tumor and its care.
Data Collection and Measures
Data were obtained from medical records and patient surveys. Using structured data forms, trained research staff collected data from clinical notes and pathology records. Clinicians were categorized according to level of training as attending physicians, resident physicians, or nurse practitioners.
Socioeconomic characteristics, comorbid illnesses, tumor-related quality of life, and health status were measured before therapy from patients' answers to a mailed survey. Comorbidity was measured using an adapted version of the Charlson index. 12, 13 Tumorrelated quality of life was measured using the 16-item version of Skindex. 14 We used a composite score calculated as the mean of the three Skindex subscale scores. 7 We also inquired about pretreatment concern about scar and worry about the treatment. Health status was measured using an adapted version of the Physical Component Summary score and Mental Component Summary score of Medical Outcomes Study 12-item Short Form Survey (SF-12). 15 In evaluating these scores, higher is healthier, and 50 is the mean norm-based standardized score.
Short-term patient satisfaction was measured 1 week after therapy using the 18-item version of the Patient Satisfaction Questionnaire (PSQ-18) 16 adapted for the treatment of skin cancer. The PSQ-18 assesses general satisfaction as well as satisfaction with six domains of care during a medical visit. Patients responded about how strongly they agreed or disagreed with statements about technical quality, interpersonal manner, communication, financial aspects of care, time spent with clinician, and accessibility of care. For each question, scores varied from 1 to 5; for overall satisfaction and the domains of care, higher scores indicate greater satisfaction with medical care.
To measure long-term satisfaction (after scar remodeling was complete), patients responded 12 months after therapy to a single global question, ''I am completely satisfied with the treatment of my skin problem.'' This item was derived from the general satisfaction items of the PSQ-18; scores varied from 1 (strongly disagree) to 5 (strongly agree). We used a global item because we reasoned that, after a year, patients would probably remember overall impressions rather than the details of their experience.
Statistical Analysis
Based on previous work about patient satisfaction and our clinical experience, we hypothesized that long-term satisfaction would be best for older, married patients; those with better pretreatment skinrelated quality of life and mental health status; those treated at the VAMC; and those treated with Mohs surgery. 9, 10, [17] [18] [19] We compared baseline clinical features in the three treatment groups using the chi-square test or the Fisher exact test, as indicated by number of subjects per cell. A one-way analysis of variance was used for comparison of continuous variables. For ordinal variables, analysis was performed using the nonparametric Kruskal-Wallis test, allowing for ties.
For multivariable analyses, we chose variables that were significant (po.20) characteristics in bivariable analyses or characteristics we judged to be clinically important. The worry variables were markedly colinear using Skindex and were therefore excluded from the multivariable model. The clinically important variables we included were pretreatment patient characteristics (patient age, sex, race, health status), tumor location, and care characteristics (treatment type, care site).
We found that the three treatment groups (destruction, excision, and Mohs) differed substantially in important patient, tumor, and care characteristics. For example, destruction was rarely performed in tumors on the head and neck. To compare treatments, we sought to compare outcomes in patients who had similar patient, tumor, and care characteristics. We restricted multivariable analyses to subjects in which sufficient numbers of patients shared patient (sex), tumor (location), and care (provider, site of care) characteristics. The case mix allowed for two sets of comparisons: patients treated with Mohs or excision and those treated with excision or destruction. We then used multivariable ordinal logistic models to evaluate independent predictors of long-term patient satisfaction, using generalized estimating equations to adjust for clustering within strata defined according to sex, site of care, provider, and tumor location.
We also performed a secondary analysis comparing Mohs and excision using matched pairs. The matched pairs were created using propensity scores resulting in 44 comparable pairs. We calculated propensity scores for each patient who had been treated with Mohs or excision using a logistic regression model. In this model, the dependent variable was whether the individual received Mohs or excision. The independent variables were sex, site of care, provider, tumor location, and variables shown to be associated with treatment choice (age, baseline Skindex composite score, and baseline SF-12 Physical and Mental Component Summary scores). We then matched patients treated with Mohs with patients treated with excision by selecting the patient pair with the most similar propensity scores, removing the pair, and selecting a pair with the next most similar propensity scores. The process was repeated until the difference in propensity scores exceeded 0.2. We then calculated the average difference in satisfaction in the matched pairs. Significance was evaluated using a permutation test. For each pair, we randomly switched the treatment labels and calculated the average difference in satisfaction. This process was repeated until it yielded the distribution of the average difference in satisfaction between the two treatments. The p-value was the proportion of times the observed absolute average difference in satisfaction exceeded the absolute average difference in satisfaction in the permuted data.
Statistical analyses were performed using Stata Statistical Software, Release 9.2 (Stata Corp., College Station, TX) and R programming language (http:// www.r-project.org).
Results
Baseline Characteristics
Treatment modalities included destruction using electrodesiccation and curettage (19%), excision (40%), and Mohs surgery (41%). Patients in the three treatment categories were similar in age, physical and mental health status, and comorbidity index but differed in education, income, baseline quality of life, and tumor characteristics. Also, excision was more likely to be performed at the VAMC, and Mohs was almost exclusively performed by attending physicians ( Table 1) .
Domains of Short-Term Satisfaction
At 1 week after therapy, general satisfaction was high (4.19 7 0.86). Overall, patients were more satisfied with the interpersonal manners of the staff, communication, and financial aspects of their care than with other domains of satisfaction. Patients in the three treatment groups had similar satisfaction with most domains, except that patients treated with Mohs and excision were somewhat more satisfied than patients treated with destruction with the technical quality of their care and with communication ( Figure 1 ). 
Predictors of Long-Term Patient Satisfaction
At 1 year after therapy, 571 patients (68%) responded about their long-term satisfaction with care. Overall, mean long-term satisfaction was high (4.08 7 1.08) and, in bivariate analyses, was related to being married, having better baseline health status and skin-related quality of life, and having tumors on the head and neck ( Table 2 ).
In the subset of patients treated with excision or Mohs (n = 315), odds of higher long-term satisfaction was independently associated with younger age, better pretreatment mental health status and skinrelated quality of life, and treatment with Mohs surgery (Figure 2A ). In the subset of patients treated with excision or destruction (n = 211), odds of higher long-term satisfaction was independently associated (po.05) only with better pretreatment mental health status ( Figure 2B ). Similar results were found in the propensity analyses.
Discussion
One week after treatment for NMSC, patients were generally satisfied with their care, but were more satisfied with the interpersonal manners of the staff, communication, and financial aspects of their care than with the technical quality of their care, time with the clinician, and accessibility of their care. Patients treated with excision or Mohs were somewhat more likely than those treated with destruction to perceive better technical quality and communication, but the four other domains of short-term satisfaction were similar across treatment groups.
One year after treatment for NMSC, overall longterm satisfaction with therapy was high regardless of treatment type. In patients treated with excision or Mohs, independent predictors of higher satisfaction were younger age, better pretreatment skinrelated quality of life, better pretreatment mental health status, and treatment with Mohs surgery. In patients treated with excision or destruction, the only independent predictor of higher satisfaction was better pretreatment mental health status.
In all comparisons, better pretreatment mental health predicted higher long-term satisfaction after treatment of NMSC. These results are consistent with a previous prospective study of dermatologic outpatients that also showed that patient satisfaction measured at 3 days and 4 weeks after a dermatologic outpatient encounter was significantly associated with previsit quality of life and psychiatric disorders. 9 A recently published review of the dermatologic literature supports the association between lower patient satisfaction and self-reported psychiatric morbidity. 8 In the comparison of patients treated with excision or Mohs, the odds of higher satisfaction were less for odds of better satisfaction . The x-axis shows odds of long-term satisfaction and the y-axis depicts the variables found to be statistically significant predictors of long-term satisfaction in the multivariable model. older patients. This finding is in contrast to previous studies that have shown that older patients are more satisfied with their care, 9, 20 independent of health status. On the other hand, the relationship between age and satisfaction is probably complex. 21 One possible explanation for our findings is that older patients may have been less tolerant of the length of the Mohs surgery procedure, although this deserves further study.
The finding that Mohs surgery was an independent predictor of higher satisfaction is potentially important. Studies of predictors of short-term and long-term satisfaction have found that short-term satisfaction is likely to be associated with patientdoctor communication, whereas long-term satisfaction is reflective of symptom outcome (symptom resolution, need for repeat visits, functional status). 20 One possible explanation for better odds of higher long-term satisfaction after Mohs surgery may be better functioning of local structures because of the tissue-sparing aspects of the technique. We have found no difference between patients treated with Mohs or excision, however, in long-term qualityof-life outcomes, including bother from appearance and effects on social or physical functioning. 7 These findings may be because quality of life and satisfaction reflect different aspects of patients' experience after therapy.
The PSQ-18 may have lacked sensitivity by failing to inquire about key factors that are known to influence overall satisfaction, such as environmental factors, interactions between nonprovider office staff and patient, 22 nursing care, 23 and time spent in the waiting room. [24] [25] [26] Another limitation is that our study participants were patients willing to complete a questionnaire, which may limit generalizability. The 571 patients who responded about satisfaction at 1 year were similar to those who did not respond in many characteristics, including age, sex, marital status, pretreatment physical and mental health, pretreatment Skindex score, and tumor type and location of treatment but had smaller tumors.
Although we have established statistically significant differences in the odds of higher satisfaction with certain patient and treatment characteristics, the clinical significance of these differences may be questioned. A previous study suggested that dermatology patients clearly differentiate between being satisfied and very satisfied with their health care. 27 For some patients, being satisfied meant that aspects of their care could have been improved, whereas being very satisfied meant that optimal care had been provided. This finding suggests that subtle statistically significant differences in global satisfaction can have clinical relevance.
In summary, long-term patient satisfaction with treatment of NMSC is related to pretreatment patient characteristics and treatment choice. These results need to be combined with data about other outcome measures to inform decision-making for treatment of NMSC.
